FDA 483 - MSD Ireland (Carlow) - April 01, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
MSD Ireland (Carlow), a biological drug manufacturer, was inspected and cited for three observations. The inspection revealed deficiencies in environmental monitoring in aseptic processing areas, a failure to thoroughly investigate unexplained discrepancies, and inadequate procedures for preventing microbiological contamination of sterile drug products, particularly regarding retesting protocols. These issues impact the quality control and assurance of biological drug products like Gardasil 9 and Capvaxive.
ID · dd59e938-7401-4e83-8a6b-5cffaf74a0e3